|Description||NVP-BAG956 is a potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo. It inhibits cellular AKT phosphorylation at Thr308 and blocks cell proliferation, causing arrest in G1 phase of the cell cycle. It slows tumor progression in mouse xenograft models.|
TEPP-46, an effective sensitizer of recombinant pyruvate kinase M2, has been found to decrease the formation of tumor in a mouse xenograft model. IC50: 92 nM (A...
BX-912 is a selective inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1) with IC50 of 12 nM; >10 fold selectivity over PKA, PKC, C-Kit, EGFR etc.
BX-517, also known as PDK1 inhibitor2, is a cell-permeable indolinone compound that acts as a potent, ATP site-targeting PDK1 inhibitor (IC50 = 6 nM). BX-517 al...
OSU 03012, a Phenanthren derivative, has been found to be a PDPK1 inhibitor that could probably be an effctive antitumor agent. It is still under Phase I trail ...
NVP-BAG956 is a potent, ATP-competitive and selective dual PI3K and PDK1 inhibitor in vitro and in vivo. It inhibits cellular AKT phosphorylation at Thr308 and ...
PDK1 inhibitor is a potent and selective inhibitor of PDK1 with potential as anticancer agent.
GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kin...